Pioneering a new frontier in cancer immunotherapy, Asgard Therapeutics has secured $33.8M in Series A funding. The privately held biotech company is developing gene therapy products that leverage in vivo direct cell reprogramming, building on its proprietary technologies to set in motion efficient and personalized immune responses.
This fresh capital will fuel Asgard's mission to establish a pipeline of off-the-shelf cancer immunotherapies. Their innovative approach aims to trigger personalized anti-cancer immune responses, ultimately benefiting cancer patients in need.


















